Latest / Early Edition with Ryan Bridge / Malcolm Mulholland: Patient Voice Aotearoa Chair on the government's expected announcement for cancer drugs

Transcript

Malcolm Mulholland: Patient Voice Aotearoa Chair on the government's expected announcement for cancer drugs · Early Edition with Ryan Bridge

• 0:02
  Speaker 1: So standing by this week allegedly for the big drug
• 0:05
  Speaker 1: announcement that the suggests in being cabinet's going to sign
• 0:07
  Speaker 1: off today to try and fix this mess they got
• 0:10
  Speaker 1: themselves into by promising stuff and they're not delivering. It's
• 0:12
  Speaker 1: understood a proposal to push a for the five to
• 0:14
  Speaker 1: six hundred million dollars into fire Mak over the next
• 0:17
  Speaker 1: four years is what's coming. The chair of Patient Voice,
• 0:19
  Speaker 1: Malcolm Mulholland is with, there's Malcolm warning to you.
• 0:22
  Speaker 2: Morning, Mike.
• 0:22
  Speaker 1: You've been excited.
• 0:24
  Speaker 2: Yeah, actually it should be a good day, a big day,
• 0:28
  Speaker 2: and he is hoping that cabinets sign off and make
• 0:31
  Speaker 2: the announcement.
• 0:32
  Speaker 1: It's a weird thing because it seems like an elegant solution.
• 0:36
  Speaker 1: The thirteen was silly given the listers out of date
• 0:39
  Speaker 1: and far Mak are independent and this, as I understand,
• 0:41
  Speaker 1: it seems to solve the problem. In other words, the
• 0:43
  Speaker 1: money goes to far Mac Farmak get to make the
• 0:45
  Speaker 1: decisions and we're often running. Is that your understanding, Yeah,
• 0:49
  Speaker 1: very much so.
• 0:49
  Speaker 2: Look when they put up the three options, Mike, I
• 0:51
  Speaker 2: think the only option that they had moving forward was
• 0:54
  Speaker 2: to give far America lump summer money to say, work
• 0:56
  Speaker 2: your way through the options for investment lists that would
• 0:58
  Speaker 2: include the thirty in Kent meds and other meds now
• 1:02
  Speaker 2: and patients will be able to get the drugs that
• 1:04
  Speaker 2: they need. So from our perspectives, this was always going
• 1:08
  Speaker 2: to be the option that the government would land on.
• 1:10
  Speaker 1: Right, does this solve the problem? Do you have any idea.
• 1:13
  Speaker 2: Or not solve the problem in terms of the turn intensemeeds?
• 1:17
  Speaker 1: Well, I mean it, it delivers on the promise, but
• 1:20
  Speaker 1: what does that buy and how many people are affected
• 1:22
  Speaker 1: and suddenly a problem goes away or not?
• 1:25
  Speaker 2: Yeah, good question. The problem doesn't go away, But what
• 1:28
  Speaker 2: we expect that will do is put a significant dent
• 1:31
  Speaker 2: in Pharmac's options for investment lists. So that's a weight
• 1:34
  Speaker 2: list that we have. We're the only country in the
• 1:36
  Speaker 2: world that has one. We would hope to see over
• 1:40
  Speaker 2: a period of time the number of drugs come off
• 1:43
  Speaker 2: that list. So, as I said to you before, that
• 1:46
  Speaker 2: will include more than just those turn intenser needs. What
• 1:48
  Speaker 2: time it will do will work their way down that
• 1:50
  Speaker 2: list according to what the rankings are. There'll be things
• 1:53
  Speaker 2: like bundled deals, so one would expect there to also
• 1:56
  Speaker 2: be other drugs that will be funded as a result,
• 1:59
  Speaker 2: and time will tellultimately where we'll leand in terms of
• 2:02
  Speaker 2: reducing the waiting list that time.
• 2:04
  Speaker 1: It is how rapidly developing the is the cancer drug business,
• 2:07
  Speaker 1: Given that I think the list is three years old
• 2:10
  Speaker 1: and it's already out of date, is it moving fast?
• 2:13
  Speaker 2: Yeah, very much so, Mike. So other jurisdictions are better
• 2:17
  Speaker 2: equipped to deal with some of the new innovative drugs. So,
• 2:21
  Speaker 2: for example, if we were to do the same list now,
• 2:24
  Speaker 2: if we were to do the same methodology that they
• 2:26
  Speaker 2: enployed three years ago, there would be, for example, about
• 2:29
  Speaker 2: five drugs in the breast cancer space that we would
• 2:33
  Speaker 2: need to fund. When that list was done three years ago,
• 2:36
  Speaker 2: there were none the same for prostate there was none.
• 2:39
  Speaker 2: My understanding how that there would be a couple more
• 2:41
  Speaker 2: for prostate. So it is moving rapidly.
• 2:43
  Speaker 1: Good stuff, Malcolm, nice to catch up with you. Appreciate
• 2:45
  Speaker 1: it very much and I hope it works out well
• 2:47
  Speaker 1: for you today, Malcolm R. Holland, you're a patient voice Artiro.
• 2:51
  Speaker 2: For more from News talks'b listen live on air or
• 2:54
  Speaker 2: online and
• 2:55
  Speaker 1: Keep our shows with you wherever you go with our
• 2:57
  Speaker 1: podcasts on IR Radio